Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile

por Mori, J, Westby, M, Tawadrous, M, van der Ryst, E, Charles, C
Publicado 2010

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc

por Lewis, ME, Jubb, B, Simpson, P, Lopatukhin, A, Kireev, D, Bobkova, M, Craig, C, van der Ryst, E, Westby, M, Butler, SL
Publicado 2021

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optim...

por Lewis, ME, Simpson, P, Mori, J, Jubb, B, Sullivan, J, McFadyen, L, van der Ryst, E, Craig, C, Robertson, DL, Westby, M
Publicado 2021